ImmunityBio, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving ImmunityBio, Inc. now
Current reporting with the operating signal separated from the noise.
ImmunityBio, Inc. (IBRX) Stock: Rebounds as UAE Approves ANKTIVA for Bladder and Lung Cancer
Investors are testing whether ImmunityBio, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
The story matters when it changes ImmunityBio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
The story matters when it changes ImmunityBio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
The story matters when it changes ImmunityBio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role
The development tests whether ImmunityBio, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The story matters when it changes ImmunityBio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Calling All ImmunityBio, Inc. (IBRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC Today To Participate in the Class Action!
The story matters when it changes ImmunityBio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest IBRX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
ImmunityBio, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →